cathvision.com

connect with usModernReimagining the capabilities of traditional recording systems. IntuitiveDelivering a familiar clinical process with clearer signals for EP procedures.PreciseRedefining precision cardiac signal quality to improve the treatment of complex arrhythmia.in the newsCathVision Announces Initiation of Clinical Study Evaluating Signal Complexity Algorithm Study Advances Efforts to Launch CARDIALYTICS Suite of Analytic ToolsCathVision Announces Close Of $7.2 Million Financing RoundFunding Will Accelerate Commercialization of the ECGenius™ System and Expand Development of Analytic ModulesCathVision Announces FDA Clearance of ECGenius™ High-Fidelity, Low-Noise EP Recording TechnologyECGenius™ Sets a New Standard for ECG Signal Acquisition, Interpretation and Therapy SupportCathVision Announces Completion of Patient Enrollment at First U.S. Clinical Trial Evaluating High-Fidelity, Low-Noise EP Recording TechnologyUniversity of Vermont Medical Center Initiates Evaluation of the ECGenius™ System as CathVision Prepares for U.S. LaunchCathVision Announces First Patient Enrollments in PVISION Multicenter Clinical StudyResearchers to Examine Efficacy of Using AI Algorithm to Confirm Pulmonary Vein IsolationCathVision Adds U.S. Profile to Its Board of DirectorsCathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, is announcing a change to its Board of Directors.PreviousNextEP RECORDING. ENHANCED.It’s time to upgrade the EP lab.The ECGenius™ System represents an evolution in cardiac signal acquisition, interpretation and therapy support, creating unprecedented opportunities for the integration of artificial intelligence-driven analytic tools.ABOUT CathVisionCathVision’s mission is to help physicians cure cardiac arrhythmia. Committed to empowering physicians to make more informed clinical decisions in the EP lab, CathVision is redefining the necessity of exceptional cardiac electrical signals to diagnose, characterize and treat the most common heart rhythm disorders. The company is focused on developing electrophysiology solutions centered around an innovative EP recording system and AI-based analytic tools.CathVision began as a graduate-level clinical research project designed to determine necessary improvements to ablation therapy and was officially launched as a company in 2013 in Denmark. The company’s presence has since expanded to the United States with operations in Minnetonka, Minnesota.historyAugust 2022CathVision raises $7.2 million from existing investors to further the advancement of AI-powered analytics and commercialization of the ECGenius™ System MAY 2022The ECGenius™ System, CathVision’s unique high-fidelity, low-noise EP recording technology, earns FDA clearance. APRIL 2022CathVision enrolls patients in first U.S.-based clinical study at the University of Vermont Medical Center. 2021CathVision enrolls first patients in PVISION Multicenter Clinical Study at four European hospitals. 2020CathVision completes an investment round of €13M to begin multi-center clinical studies. 2019CathVision expands its board of directors and is awarded a €2.2M grant from the Horizon 2020 programs. 2018CathVision obtains IOS13485 certification and establishes a presence in the U.S. 2017CathVision closes its first multi-million-dollar round of funding. 2013CathVision is officially incorporated. LeadershipMads Emil MatthiesenCo-Founder & CEO Mads Emil MatthiesenCo-Founder & CEO Mads Matthiesen co-founded CathVision in 2010 and currently serves as the company’s CEO. He has extensive experience in the field of cardiology as both a business leader and biomedical engineer and has spent more than a decade involved in the development of innovative medical devices and research in Europe and the U.S. Under Matthiesen’s leadership, CathVision achieved FDA clearance of the company’s first technology – the ECGenius™ System. He also has led efforts for the product’s commercial launch in the U.S. Matthiesen is a graduate of the Technical University of Denmark and holds a degree in biomedical engineering. He has completed additional education training at MIT and Harvard in the areas of medical device and implant design. Prior to the incorporation of CathVision in 2013, Matthiesen worked as a management consultant at the Boston Consulting Group, Copenhagen. Email:mem@cathvision.comRune ØrndrupCo-Founder & CFO Rune ØrndrupCo-Founder & CFO Rune Ørndrup helped co-found CathVision in 2010 and has served as the company’s CFO since 2019. He has a diverse background in both established corporate organizations and agile startups, including extensive experience in finance and global scale operations in the U.S., Asia, and Europe. He also brings a wealth of knowledge in legal, HR, and IT. During his tenure at CathVision, Ørndrup has successfully steered multiple funding rounds totaling more than 20 million EUR, and he has also brought more than 30 million USD in funding for tech startup Labster. Ørndrup formerly held positions at KPMG, Deloitte, Pandora, Mailbird and Labster, and he continues to play an active role in the Danish startup ecosystem, giving his time and support to future entrepreneurs as a jury member for Venture Cup Denmark. He holds a master’s degree in Management Accounting and Control from Aarhus University. Allan Gersfelt-LarsenVP EngineeringAllan Gersfelt-LarsenVP EngineeringAllan Gersfelt-Larsen has served as CathVision’s VP Engineering since joining the team in 2019. As a senior R&D leader, he brings more than 15 years of in-depth experience in product development within the areas of medical devices and biotechnology. Since his arrival, Gersfelt-Larsen has helped grow the CathVision R&D team from less than a handful of employees to more than 20 highly skilled developers and engineers. His leadership in product manufacturing has been instrumental in the development and FDA clearance of the ECGenius System. Gersfelt-Larsen holds a master’s degree in Computer Systems Engineering from the University of Southern Denmark and has completed additional leadership training at INSEAD business school in France. Prior to joining CathVision, he held senior leadership positions with Philips and Asseco Group. Board of DirectorsSøren Thestrup-NielsenChairmanSøren Thestrup-NielsenChairmanDr. Thestrup-Nielsen, MD, has spent 25 years in the medical device industry, first at Boston Scientific and later at Danaher Corporation where he built the diagnostics business with responsibility for M&A. He was previously Chairman of Althea Group, board member at Oncimmune and co-founder of Sensimed AG. He holds an M.D. from the University of Copenhagen, practiced five years as a general & vascular surgeon, and received an MBA from the IMD in Lausanne, Switzerland.Denis GestinBoard MemberDenis GestinBoard MemberMr. Gestin has over 30 years of experience in the management and commercial development of medical technologies companies. He began his career at Ela Medical Inc. (LivaNova), and later joined St. Jude Medical where he most recently was President of the International Division (OUS), then Senior Vice President of Global Commercial Integration after the merger with Abbott Laboratories. Mr. Gestin serves as Chairman of Holistick and Endo Tools Therapeutics. He is a graduate of EDC Paris Business School.Meghna EichelbergerBoard MemberMeghna EichelbergerBoard MemberMs. Eichelberger serves as Partner and Associate Director of Medical Technologies at The Boston Consulting Group (BCG). She combines a digital innovation profile with an integrated view of commercial excellence and market/clinical development. Prior to joining BCG, Eichelberger worked at C.R. Bard where she was a franchise leader for both disposables and capital equipment, and led the atrial fibrillation franchise.Tonni Bülow-NielsenBoard MemberTonni Bülow-Niel

Category: Health

City: Copenhagen

Country: Denmark (DK)

Platform: WooCommerce

Technologies used: reCAPTCHA